$MANKIND

Mankind Pharma is back in focus after delivering another steady quarter, supported by strong domestic formulations growth and continued expansion in its chronic therapy portfolio. The company has been strengthening its presence in high-growth segments such as cardiovascular, anti-diabetic and respiratory therapies, helping it maintain momentum despite a competitive pharma landscape. Strong domestic business continues to drive growth Focus on chronic therapies improving product mix Healthy cash generation and strong balance sheet Pharma sector attracting investors as a defensive play amid market volatility What makes Mankind Pharma interesting is its ability to consistently grow while maintaining profitability. With healthcare spending rising and chronic disease treatments becoming a larger part of the market, investors are keeping a close watch on the company. From a technical perspective, the stock remains near key support levels and any positive trigger from earnings, management commentary or sector-wide strength could bring renewed buying interest. A quality pharma name that remains on many investors' watchlists. Disclaimer: This is for educational purposes only and not investment advice.